Featured Research

from universities, journals, and other organizations

San Francisco Study Shows Antiretroviral Treatment Continues To Improve AIDS Survival

Date:
July 18, 2000
Source:
University Of California, San Francisco
Summary:
A study from the San Francisco Department of Public Health and University of California, San Francisco found that treatment with potent antiretroviral therapy continues to significantly improve how long AIDS patients survive with the disease. The findings do not support concerns voiced among some researchers that such therapy might lose its effectiveness over time.

A study from the San Francisco Department of Public Health and University of California, San Francisco found that treatment with potent antiretroviral therapy continues to significantly improve how long AIDS patients survive with the disease. The findings do not support concerns voiced among some researchers that such therapy might lose its effectiveness over time.

"Our data show a very significant survival benefit from use of antiretroviral therapy, particularly when it includes a protease inhibitor," said Sandra Schwarcz, MD, MPH, the principal investigator of the study and a member of the SF Department of Public Health AIDS Surveillance Unit.

Schwarcz reported the findings today (July 13) at the XIII International AIDS Conference in Durban, South Africa.

The study included 2,607 persons who were diagnosed with one of the AIDS-defining opportunistic illnesses between 1995-97 and 3,228 persons diagnosed with either an opportunistic illness or low CD4 cell count within the same time period. Researchers analyzed survival trends over time in the first group of patients and looked at how various forms of treatment affected the risk of death in the latter group.

Because San Francisco was one of the first AIDS epidemic centers in North America, disease trends have often been observed first in the city, said Schwarcz. The number of AIDS deaths in San Francisco reached a plateau between 1992-94 and then declined in 1995, as highly active antiretroviral therapy (HAART) was introduced. The years 1996 and 97 saw the greatest (59 percent) decline in AIDS deaths in the city, but between 1997-98 the decline dropped to 30 percent, prompting speculation that the survival benefit associated with HAART might have waned.

To determine whether this was so, researchers at the San Francisco DPH AIDS Surveillance Unit and a UCSF colleague used comprehensive surveillance data to carefully evaluate trends in AIDS survival between 1995-97 and to assess the impact of treatment on the risk of death after AIDS.

The DPH AIDS surveillance registry includes detailed follow-up information on treatment and treatment outcomes, said Schwarcz. Working with this registry, researchers have access to information on the dates and types of AIDS-defining opportunistic illnesses, CD4 test results, and the types and starting dates of antiretroviral therapy and prophylactic medications. Information is collected on patients at the time of diagnosis and is updated annually.

In this study, researchers looked at survival in two ways: by determining the median (midpoint) time of survival for patients and determining the proportion of persons surviving two years after diagnosis. They found that survival increased by both measures in the three-year study period. Median survival was 24 months for persons diagnosed in 1995, 51 months for persons diagnosed in 1996, and could not yet be determined for persons diagnosed in 1997. The proportion of persons surviving two years after diagnosis was 50 percent for those diagnosed in 1995, 69 percent for those diagnosed in 1996, and 70 percent for those diagnosed in 1997.

The researchers also found that use of antiretroviral therapy reduced the risk of death, particularly if it included a protease inhibitor. Patients who received this type of therapy (HAART) after being diagnosed with AIDS, reduced their risk of death by 60 percent, said Schwarcz.

"This finding, combined with other data that predict little negative effect associated with drug resistance and the potential for reduced HIV transmission from persons receiving therapy, supports efforts to expand the use of HAART," said Schwarcz.

The study also determined that the risk of death was increased for persons aged 40 or greater at the time of AIDS diagnosis, for those whose initial AIDS diagnosis included an opportunistic illness, and for both homosexual and heterosexual injection drug users. The risk of death was lower for persons with higher CD4 cell counts at diagnosis.

Co-investigators included Ling Hsu, MPH, San Francisco DPH AIDS Surveillance Unit; Eric Vittinghoff, PhD, UCSF Center for AIDS Prevention Studies; Mitchell H. Katz, MD, director of the San Francisco DPH; and Willi McFarland, MD, PhD, San Francisco DPH HIV Seroepidemiology Unit and UCSF Center for AIDS Prevention Studies.


Story Source:

The above story is based on materials provided by University Of California, San Francisco. Note: Materials may be edited for content and length.


Cite This Page:

University Of California, San Francisco. "San Francisco Study Shows Antiretroviral Treatment Continues To Improve AIDS Survival." ScienceDaily. ScienceDaily, 18 July 2000. <www.sciencedaily.com/releases/2000/07/000717073659.htm>.
University Of California, San Francisco. (2000, July 18). San Francisco Study Shows Antiretroviral Treatment Continues To Improve AIDS Survival. ScienceDaily. Retrieved September 15, 2014 from www.sciencedaily.com/releases/2000/07/000717073659.htm
University Of California, San Francisco. "San Francisco Study Shows Antiretroviral Treatment Continues To Improve AIDS Survival." ScienceDaily. www.sciencedaily.com/releases/2000/07/000717073659.htm (accessed September 15, 2014).

Share This



More Health & Medicine News

Monday, September 15, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Respiratory Virus Spreads To Northeast, Now In 21 States

Respiratory Virus Spreads To Northeast, Now In 21 States

Newsy (Sep. 14, 2014) The respiratory virus Enterovirus D68, which targets children, has spread from the Midwest to 21 states. Video provided by Newsy
Powered by NewsLook.com
Shocker: Journalists Are Utterly Addicted To Coffee

Shocker: Journalists Are Utterly Addicted To Coffee

Newsy (Sep. 13, 2014) A U.K. survey found that journalists consumed the most amount of coffee, but that's only the tip of the coffee-related statistics iceberg. Video provided by Newsy
Powered by NewsLook.com
Contagious Respiratory Illness Continues to Spread Across U.S.

Contagious Respiratory Illness Continues to Spread Across U.S.

Reuters - US Online Video (Sep. 12, 2014) Hundreds of children in several states have been stricken by a serious respiratory illness that is spreading across the U.S. Linda So reports. Video provided by Reuters
Powered by NewsLook.com
Ebola Batters Sierra Leone Economy Too

Ebola Batters Sierra Leone Economy Too

Reuters - Business Video Online (Sep. 12, 2014) The World Health Organisation warns that local health workers in West Africa can't keep up with Ebola - and among those countries hardest hit by the outbreak, the economic damage is coming into focus, too. As David Pollard reports, Sierra Leone admits that growth in one of the poorest economies in the region is taking a beating. Video provided by Reuters
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

    Technology News



    Save/Print:
    Share:

    Free Subscriptions


    Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

    Get Social & Mobile


    Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

    Have Feedback?


    Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
    Mobile: iPhone Android Web
    Follow: Facebook Twitter Google+
    Subscribe: RSS Feeds Email Newsletters
    Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins